C4 Therapeutics (CCCC) Cash from Investing Activities (2019 - 2026)

C4 Therapeutics has reported Cash from Investing Activities for 8 years, with the latest figure at $16.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 44.54% year-over-year to $16.2 million; the trailing twelve-month figure through Mar 2026 stood at -$21.6 million (down 169.03% YoY), and the FY2025 full-year result was -$8.6 million, up 83.22% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $16.2 million, up from -$80.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $57.7 million in Q3 2023, with the low at -$80.7 million in Q4 2025.
• Average Cash from Investing Activities over 5 years is $10.2 million, with a median of $15.1 million recorded in 2023.
• Peak annual rise in Cash from Investing Activities reached 2422.22% in 2025, while the deepest fall reached 690.59% in 2025.
• Tracing CCCC's Cash from Investing Activities over 5 years: stood at $9.3 million in 2022, then surged by 244.09% to $31.9 million in 2023, then sank by 57.21% to $13.7 million in 2024, then slumped by 690.59% to -$80.7 million in 2025, then surged by 120.01% to $16.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $16.2 million (Q1 2026), -$80.7 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.

Peer Comparison